Please find enclosed herewith the Audited Financial Results for the Quarter and Year Ended March 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Parnax Lab's board, meeting on May 27, 2025, approved audited standalone and consolidated results for Q4 and FY25, with auditors (C.N. Patel & Co.) issuing an unmodified opinion. On a standalone basis, full-year revenue from operations fell about 5.7% to ₹701.90 lakhs (vs ₹744.04 lakhs in FY24), while standalone net profit dropped roughly 23.5% to ₹139.46 lakhs; the standalone business also slipped into a loss of ₹8.36 lakhs in Q4 FY25 against a profit of ₹17.33 lakhs a year ago. Consolidated results were far stronger, driven by subsidiary Naxpar Pharma Private Limited, which contributed revenues of ₹18,243.62 lakhs and net profit of ₹1,014.47 lakhs. Consolidated revenue from operations was nearly flat at ₹18,773.78 lakhs, but consolidated profit after tax grew nearly 20% to ₹1,153.92 lakhs (vs ₹962.48 lakhs), lifting consolidated EPS to ₹10.05 from ₹8.38. Operating cash flow remained positive at the consolidated level (₹3,230.15 lakhs).
For shareholders, the consolidated story is positive thanks to the Naxpar Pharma subsidiary, which is doing most of the heavy lifting on growth and profits, but the shrinking standalone pharma-formulations business and the small Q4 standalone loss are points to watch. The clean (unmodified) audit opinion and positive operating cash flow are reassuring, though the standalone trend may keep the stock from rerating until the core business stabilises.